Related Experiment Video
Updated: Sep 10, 2025
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Meta-analysis on the safety and efficacy of Erdafitinib in treating FGFR1-4 mutated solid tumors
Jiyu Huang1, Zihan Wang1, Fei Zhao1
1Medical College, Northwest University for Nationalities, Lanzhou, China.
Objective:
This article aims to analyze the safety and efficacy of Erdafitinib in the treatment of patients with advanced solid tumors harboring FGFR1-4 mutations.
Methods:
Search for relevant articles in databases such as PubMed, Embase, The Cochrane Library, Web of Science, and CNKI, covering the period from their establishment to October 25, 2024. Summarize the adverse drug reaction (AE) data, overall survival (OS), median progression-free survival (PFS), objective response rate (ORR), and other relevant data for patients with advanced solid tumors treated with Erdafitinib for FGFR1-4 mutations. Conduct a meta-analysis on the corresponding summarized data using the software Stata 18.0.
Results:
Through our search, we identified a total of 10 articles involving 1019 patients. In urothelial carcinoma, the most prevalent adverse reactions are hyperphosphatemia (78.5%), diarrhea (56.5%), and stomatitis (51.1%). The most frequently reported adverse reactions in other solid tumors are hyperphosphatemia (66.5%), dry mouth (48.5%), and diarrhea (44.9%). Patients with urothelial carcinoma treated with Erdafitinib exhibit higher median progression-free survival (PFS) and objective response rate (ORR) compared to those treated with other solid tumor therapies.
Conclusion:
Current evidence indicates that Erdafitinib exhibits certain therapeutic efficacy in the treatment of advanced solid tumors harboring FGFR1-4 mutations, with the most pronounced therapeutic effect observed in urothelial carcinoma. The efficacy of Erdafitinib in treating other solid tumors requires further confirmation through larger-scale studies involving a broader range of FGFR1-4 mutant tumors.
Insights
Erdafitinib shows efficacy in treating advanced solid tumors with FGFR1-4 mutations, particularly urothelial carcinoma. Further research is needed to confirm its effectiveness in other solid tumors.
Area of Science:
- Oncology
- Pharmacology
- Genetics
Background:
- Fibroblast Growth Factor Receptor (FGFR) mutations are implicated in various advanced solid tumors.
- Targeted therapies like Erdafitinib offer potential treatment avenues for these mutations.
Purpose of the Study:
- To analyze the safety and efficacy of Erdafitinib in patients with advanced solid tumors harboring FGFR1-4 mutations.
- To evaluate treatment outcomes, including adverse events and survival data.
Main Methods:
- A systematic literature search was conducted across major databases up to October 25, 2024.
- Data on adverse drug reactions (AEs), overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) were extracted.
- A meta-analysis was performed using Stata 18.0.
Main Results:
- Ten articles involving 1019 patients were included.
- Common AEs in urothelial carcinoma: hyperphosphatemia (78.5%), diarrhea (56.5%), stomatitis (51.1%).
- Common AEs in other solid tumors: hyperphosphatemia (66.5%), dry mouth (48.5%), diarrhea (44.9%).
- Erdafitinib demonstrated superior PFS and ORR in urothelial carcinoma compared to other solid tumors.
Conclusions:
- Erdafitinib shows therapeutic efficacy in advanced solid tumors with FGFR1-4 mutations, most notably in urothelial carcinoma.
- Larger studies are needed to confirm efficacy in a broader range of FGFR1-4 mutant solid tumors.
More Related Videos
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
